Date: 2013-04-30
Type of information: R&D agreement
Compound: cancer treatments based on epigenetic drug mechanisms
Company: Evotec (Germany) Dana Farber Cancer Institute (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: * On April 30, 2013, the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec have announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms. The goal of the collaboration is to validate emerging epigenetic targets for oncology indications and to demonstrate the drugability of the selected target families. Evotec, Dana-Farber and Dana-Farber’s Belfer Institute for Applied Cancer Science will invest in enabling technologies, experimental target validation and the generation of chemical matter by leveraging existing expertise and platforms. The collaboration will be fuelled by substantial scientific contributions from the three organisations aligned on the objective to develop therapies that address unmet medical needs for cancer patients.
Financial terms: Further details and commercial terms of the cooperation are not disclosed.
Latest news:
